Shopping Cart
- Remove All
- Your shopping cart is currently empty
Gly-β-MCA is an orally bioactive, enteroselective and potent inhibitor of the farnesoid X receptor (FXR), a bile acid, used in the study of obesity and diabetes.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | $199 | In Stock |
Description | Gly-β-MCA is an orally bioactive, enteroselective and potent inhibitor of the farnesoid X receptor (FXR), a bile acid, used in the study of obesity and diabetes. |
In vitro | Gly-β-MCA is an effective intestinal selective farnesoid X receptor (FXR) inhibitor, belonging to the bile acids class[1]. Gly-β-MCA (Gly-MCA) exhibits resistance to hydrolysis by BSH (bile salt hydrolase)[1]. |
In vivo | Gly-β-MCA (Gly-MCA, oral administration, 10 and 50 mg/kg) can prevent and treat diet-induced and genetic obesity, insulin resistance, and hepatic steatosis in mice, without causing systemic, hepatic, or intestinal toxicity[1].Gly-MCA does not increase fecal LCN-2 levels, indicating that Gly-MCA does not induce intestinal inflammation[1]. |
Molecular Weight | 465.62 |
Formula | C26H43NO6 |
Cas No. | 66225-78-3 |
Smiles | C[C@H](CCC(=O)NCC(O)=O)C1CCC2C3[C@@H](O)[C@@H](O)[C@@H]4C[C@H](O)CC[C@]4(C)C3CC[C@]12C |
Relative Density. | 1.213 g/cm3 (Predicted) |
Storage | store at low temperature,keep away from direct sunlight | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | ||||||||||||||||||||||||||||||
Solubility Information | H2O: <0.1 mg/mL (Insoluble) DMSO: 50 mg/mL (76.42 mM), Sonication is recommended. | ||||||||||||||||||||||||||||||
Solution Preparation Table | |||||||||||||||||||||||||||||||
DMSO
|
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.